Cargando…

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

BACKGROUND: Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. METHODS: Study design: COMBIVAS is a randomised, double-blind, placebo-controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClure, Mark E., Gopaluni, Seerapani, Wason, James, Henderson, Robert B., Van Maurik, Andre, Savage, Caroline C.O., Pusey, Charles D., Salama, Alan D., Lyons, Paul A., Lee, Jacinta, Mynard, Kim, Jayne, David R., Jones, Rachel B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007661/ https://www.ncbi.nlm.nih.gov/pubmed/36906660 http://dx.doi.org/10.1186/s13063-023-07218-y

Ejemplares similares

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Clinical Trials in Vasculitis
por: Gopaluni, Seerapani, et al.
Publicado: (2016)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
por: McAdoo, Stephen P, et al.
Publicado: (2019)

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial
por: Gopaluni, Seerapani, et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
por: Gopaluni, Seerapani, et al.
Publicado: (2022)

Management of ANCA-associated vasculitis: Current trends and future prospects
por: Hamour, Sally, et al.
Publicado: (2010)

Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2018)

Long- term outcome of paediatric patients with ANCA vasculitis
por: Arulkumaran, Nishkantha, et al.
Publicado: (2011)

Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis
por: Rathmann, Jens, et al.
Publicado: (2022)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis
por: Prendecki, Maria, et al.
Publicado: (2018)

Rituximab used for simultaneous treatment of PR3‐ANCA positive vasculitis associated with rheumatoid arthritis: A case report
por: Yamada, Akihiro, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Rhinologic and sinonasal changes in PR3 ANCA pulmonary vasculitis
por: Zycinska, K, et al.
Publicado: (2010)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

What you should know about PR3-ANCA: Evidence for the role of T cells in the pathogenesis of systemic vasculitis
por: Clayton, Abigail R, et al.
Publicado: (2000)

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
por: Lenert, Aleksander, et al.
Publicado: (2015)

Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis
por: Zycinska, K, et al.
Publicado: (2009)

Acute PR3-ANCA vasculitis in an asymptomatic COVID-19 teenager
por: Wintler, Taylor, et al.
Publicado: (2021)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

ANCA Associated Vasculitis Subtypes: Response [Letter]
por: Merkel, Peter A, et al.
Publicado: (2022)

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
por: Mariette, Xavier, et al.
Publicado: (2022)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Membrane expression of neutrophil proteinase 3 (PR3) is associated with relapse in PR3-ANCA related vasculitis
por: Rarok, AA, et al.
Publicado: (2002)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Salama, Alan D.
Publicado: (2019)

Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement
por: Zycinska, K, et al.
Publicado: (2009)

Chemokine/Cytokine Levels Correlate with Organ Involvement in PR3-ANCA-Associated Vasculitis
por: Müller-Deile, Janina, et al.
Publicado: (2021)

Specific IgG glycosylation differences precede relapse in PR3-ANCA associated vasculitis patients with and without ANCA rise
por: Wojcik, Iwona, et al.
Publicado: (2023)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_13gh7k6593n2qgbffo48s0qj04